InvestSMART

Bubs Australia Limited (ASX:BUB)

ALERT: Price-sensitive ASX Announcement for BUB
Current share price for BUB : $0.080 -0.05 (-38.46%)+
Announcement
Release
30 Jan 2026 1:13PM
Price at Release
$0.130
Full Release
download
Summary
Bubs Australia Limited announced strong financial performance for the first half of the fiscal year 2026, with notable revenue growth mainly driven by the US market. The company saw a 14% increase in net revenue compared to last year, with the USA market contributing a substantial 47% rise in revenue. Despite challenges in other regions, Bubs has stabilized its operations and expects further improvements. The company is close to obtaining FDA approval for its products and maintains a solid cash position with ample liquidity to support ongoing operations.
Key Points
  • Bubs Australia Limited reported a 14% increase in half-year net revenue to $55.5 million compared to the previous year.
  • Q2 FY26 net revenue rose by 17% to $29.9 million from Q1 FY26.
  • The USA market is highlighted as the key growth engine, with a 47% increase in half-year net revenue.
  • Net cash used in operating activities for Q2 was $3.5 million, contributing to a year-to-date total of $7.957 million.
  • Bubs held $9.9 million cash at the end of December 2025, with an additional $10 million in undrawn debt facilities.
  • Payments amounting to $380k were made to Key Management Personnel and $65k for Directors’ remuneration.
  • Bubs is on track to receive FDA approval, with ongoing facilitation for the importation and distribution of its infant formula products in the US.
  • The company maintained a gross margin of 49.3%, slightly down from 50% in the previous corresponding period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.